← Back to Home

Lung cancer consolidation trial: benmelstobart delays progression, but adding anlotinib increases toxicity

Extending disease control after chemoradiotherapy is an important challenge for patients with inoperable lung cancer. The phase 3 R-ALPS trial supports the efficacy of benmelstobart, but the combination did not show a statistically significant additional benefit and increased serious and fatal adverse effects.

By SURL BioNews

For patients with inoperable stage III non-small cell lung cancer whose disease has temporarily stabilized after radiotherapy and chemotherapy, the next step is to delay further progression for as long as possible. The R-ALPS trial, published October 29 in *JAMA Oncology*, provides new evidence for this phase of treatment: benmelstobart improved progression-free survival, but adding anlotinib did not demonstrate a statistically significant additional benefit and increased treatment risks.

This double-blind, randomized phase 3 trial was conducted at 42 centers in China and enrolled 553 patients whose disease had not progressed after concurrent or sequential chemoradiotherapy. Overall, 209 patients received the combination, 212 received benmelstobart alone, and 132 received placebo. The primary endpoint was progression-free survival assessed by an independent review committee, defined as the time from treatment assignment to disease progression or death.

The trial was conducted in two stages. In the first stage, 390 patients were assigned to three groups. Median progression-free survival was 15.1 months in the combination group, 9.7 months in the monotherapy group, and 4.2 months in the placebo group. Both benmelstobart-containing regimens showed statistically significant differences compared with placebo, indicating that the treatment helped extend disease control after chemoradiotherapy.

Whether the combination was superior to monotherapy, however, requires a direct comparison. The second stage enrolled another 163 patients, who were assigned to the two active treatment groups. In the combined data from both stages, median progression-free survival was 17.4 months with the combination and 11.2 months with monotherapy. Despite the numerical difference, the hazard ratio was 0.82, with a 95% confidence interval of 0.63 to 1.08, which did not reach statistical significance. A longer median alone therefore cannot establish a definite benefit from adding the drug; these figures also reflect a different analysis population from that of the first stage.

Safety showed a more pronounced difference. Grade 3 to 5 treatment-related adverse events occurred in 48.8% of patients in the combination group, 29.4% in the monotherapy group, and 19.7% in the placebo group; fatal events occurred in 7.2%, 1.4%, and 1.5%, respectively. With additional efficacy still unconfirmed, the combination’s higher rates of serious and fatal toxicity represent a cost that cannot be overlooked when assessing its clinical value.

These study data were previously presented at the 2025 American Society of Clinical Oncology Annual Meeting. Sino Biopharmaceutical’s announcement in June of that year reported the same patient numbers across the three groups and the same rates of grade 3 or higher treatment-related adverse events as the journal report. The company also stated at the time that marketing applications for benmelstobart alone or in combination with anlotinib for this indication had been accepted by China’s Center for Drug Evaluation in April 2025; acceptance itself does not mean approval.

The results support the activity of benmelstobart as consolidation therapy after chemoradiotherapy and define the limits of the evidence for routinely adding anlotinib. However, improved progression-free survival cannot be directly equated with longer overall survival. The trial used placebo as its comparator and therefore cannot establish how the treatment compares with other existing consolidation immunotherapies. The study was conducted entirely in China, and nearly 90% of participants were men, leaving room for further assessment of whether the findings apply equally to other populations.

References

  1. JAMA Oncology
  2. Sino Biopharmaceutical Limited